BRIEF-Valeant updates on settlement agreements related to Salix unit
Aug 9 (Reuters) - Valeant Pharmaceuticals
* Estimated legal liability, initially measured at fair value on date of Salix acquisition, should be reduced by $39 million
* Co and the states have executed settlement agreements concerning the states' portion of the settlement related to Salix
* Pursuant to terms of agreements, co will make a payment of about $8 million plus interest by august 18, 2016
* Following execution of settlement concerning federal claims against Salix, co concluded its estimated legal liability relating to this matter
* Adjustment was recorded in other income in Q2 of 2016 in the co's consolidated statement of loss Source text: bit.ly/2aQ7jYe Further company coverage:
© Thomson Reuters 2017 All rights reserved.